Loading…
RIVA RIVAROXABAN is a brand name for Rivaroxaban, supplied as a tablet. The medicine, its uses, side effects and dosage are the same regardless of brand.
Used for: RIVA RIVAROXABAN (rivaroxaban) film-coated tablet (10 mg, 15 mg, 20 mg) is indicated for the: • prevention of venous thromboembolic events (VTE) in patients who have undergone elective total hip replacement (THR) or total knee replacement (TKR) surgery. • treatment of venous thromboembolic events (deep vein thrombosis…
Verbatim from this product's HC label. Tap a section to expand.
). RIVA RIVAROXABAN (rivaroxaban) film-coated tablet (20 mg) is indicated for the: • treatment of venous thromboembolic events (VTE) and prevention of VTE recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment (see 4 DOSAGE AND ADMINISTRATION).
Acute Pulmonary Embolus in hemodynamically unstable patients, or in those requiring thrombolysis or pulmonary embolectomy For the treatment of VTE, RIVA RIVAROXABAN is not recommended as an alternative to unfractionated heparin in patients with pulmonary embolus who are hemodynamically unstable, or who may receive thrombolysis or pulmonary embolectomy, since the safety and efficacy of rivaroxaban have not been established in these clinical situations (see 4 DOSAGE AND ADMINISTRATION).
1 Pediatrics Pediatrics (< 18 years of age): In children less than 18 years of age, the safety and efficacy of rivaroxaban have not been established for indications other than treatment of venous thromboembolic events (VTE) and prevention of VTE recurrence.
Therefore, RIVA RIVAROXABAN is not recommended for use in children below 18 years of age for indications other than the treatment of VTE and prevention of VTE recurrence. 3 Pediatrics). 4 Geriatrics and Renal Impairment, and 4 DOSAGE AND ADMINISTRATION – Renal Impairment and Geriatrics (>65 years of age)).
Safety and efficacy data are available (see 14 CLINICAL TRIALS). , recent cerebral infarction (hemorrhagic or ischemic), active peptic ulcer disease with recent bleeding, patients with spontaneous or acquired impairment of hemostasis • Concomitant systemic treatment with strong inhibitors of both CYP 3A4 and P-glycoprotein (P- gp), such as cobicistat, ketoconazole, itraconazole, posaconazole, or ritonavir (see 7 WARNINGS AND PRECAUTIONS – Drug Interactions) • Concomitant treatment with any other anticoagulant, including o unfractionated heparin (UFH), except at doses used to maintain a patent central venous or arterial catheter, o low molecular weight heparins (LMWH), such as enoxaparin and dalteparin, o heparin derivatives, such as fondaparinux, and o oral anticoagulants, such as warfarin, dabigatran, apixaban, edoxaban, except under circumstances of switching therapy to or from RIVA RIVAROXABAN.
2 Breast-feeding) • Hypersensitivity to RIVA RIVAROXABAN (rivaroxaban) or to any ingredient in the formulation, (see
1 Adverse Reaction Overview Prevention of VTE after THR or TKR The safety of rivaroxaban 10 mg has been evaluated in three randomized, double- blind, active-control Phase III studies (RECORD 1, RECORD 2, and RECORD 3). In the Phase III studies, 4657 patients undergoing total hip replacement or total knee replacement surgery were randomized to rivaroxaban, with 4,571 patients actually receiving rivaroxaban.
In RECORD 1 and 2, a total of 2209 and 1228 THR patients, respectively, were randomized to rivaroxaban 10 mg od. In RECORD 1, the treatment period for both groups was 35±4 days postoperatively. In RECORD 2, patients randomized to rivaroxaban were treated for 35 ±4 days postoperatively, and patients randomized to enoxaparin received placebo after day 12±2 until day 35±4 postoperatively.
In RECORD 3, a total of 1220 TKR patients were randomized to rivaroxaban 10 mg od, and both groups received study drug until day 12±2 postoperatively. Treatment of VTE and Prevention of Recurrent DVT and PE The safety of rivaroxaban has been evaluated in four Phase III trials with 6790 patients treated up to 21 months.
Patients were exposed to 15 mg rivaroxaban twice daily for 3 weeks followed by: • 20 mg once daily (EINSTEIN DVT, EINSTEIN PE) or • 20 mg once daily after at least 6 months of treatment for DVT or PE (EINSTEIN Extension), or • 20 mg or 10 mg rivaroxaban once daily after at least 6 months of treatment for DVT or PE (EINSTEIN CHOICE).
The mean treatment duration was 194 days in EINSTEIN DVT, 183 days in EINSTEIN PE, 188 days in EINSTEIN Extension and 290 days in EINSTEIN CHOICE. 2% for ASA (EINSTEIN CHOICE). Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation (SPAF) In the pivotal double-blind ROCKET AF study, a total of 14,264 patients with atrial fibrillation at risk for stroke and systemic embolism were randomly assigned to treatment with either rivaroxaban (7,131) or warfarin (7,133) in 45 countries.
, Anticoagulant-Related Nephropathy 03/2025 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES ...........................................................................................
2 TABLE OF CONTENTS ............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION .....................................................................
4 1 INDICATIONS .............................................................................................................. 1 Pediatrics.................................................................................................................
2 Geriatrics ................................................................................................................. 5 2 CONTRAINDICATIONS .................................................................................................
5 4 DOSAGE AND ADMINISTRATION................................................................................. 1 Dosing Considerations ............................................................................................ 2 Recommended Dose and Dosage Adjustment .......................................................
4 Administration ...................................................................................................... 5 Missed Dose ..........................................................................................................
12 5 OVERDOSAGE........................................................................................................... 12 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING ............................... 14 7 WARNINGS AND PRECAUTIONS ................................................................................
, recent cerebral infarction (hemorrhagic or ischemic), active peptic ulcer disease with recent bleeding, patients with spontaneous or acquired impairment of hemostasis • Concomitant systemic treatment with strong inhibitors of both CYP 3A4 and P-glycoprotein (P- gp), such as cobicistat, ketoconazole, itraconazole, posaconazole, or ritonavir (see 7 WARNINGS AND PRECAUTIONS – Drug Interactions) • Concomitant treatment with any other anticoagulant, including o unfractionated heparin (UFH), except at doses used to maintain a patent central venous or arterial catheter, o low molecular weight heparins (LMWH), such as enoxaparin and dalteparin, o heparin derivatives, such as fondaparinux, and o oral anticoagulants, such as warfarin, dabigatran, apixaban, edoxaban, except under circumstances of switching therapy to or from RIVA RIVAROXABAN.
2 Breast-feeding) • Hypersensitivity to RIVA RIVAROXABAN (rivaroxaban) or to any ingredient in the formulation, (see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING).
Not medical advice. Always read the patient information leaflet and follow your prescriber or pharmacist.
Other brands of Rivaroxaban in Canada.
Know a brand we are missing in Canada? Suggest a brand →
Brand names are compiled from public regulatory records for active-ingredient mapping only. Drugvu is not affiliated with any manufacturer. This is not medical advice.
0. The safety population included patients who were randomized and took at least 1 dose of study medication. In total, 14,236 patients were included in the safety population, with 7,111 and 7,125 patients in rivaroxaban and warfarin groups, respectively.
The median time on treatment was 19 months and overall treatment duration was up to 41 months. 2% in the warfarin group. 5 mg bid in combination with ASA 100 mg od (9,152), rivaroxaban 5 mg bid alone (9,117) or ASA 100 mg od (9,126).
The intention-to-treat (ITT) analysis set includes all randomized subjects. The median duration of treatment for any of the antithrombotic study drugs was 615 days and was similar for all 3 treatment groups. 6% in the ASA 100 mg od arm.
Bleeding Due to the pharmacological mode of action, rivaroxaban is associated with an increased risk of occult or overt bleeding from any tissue and organ (see 7 WARNINGS AND PRECAUTIONS – Bleeding, and Drug Interactions). , patients with uncontrolled severe arterial hypertension and/or on concomitant medication affecting hemostasis (see Table 4).
The signs, symptoms, and severity (including fatal outcome) will vary according to the location and degree or extent of the bleeding and/or anemia. Hemorrhagic complications may present as weakness, paleness, dizziness, headache or unexplained swelling, dyspnea, and unexplained shock.
In some cases, as a consequence of anemia, symptoms of cardiac ischemia like chest pain or angina pectoris have been observed. Known complications secondary to severe bleeding such as compartment syndrome and renal failure due to hypoperfusion have been reported for rivaroxaban.
Therefore, the possibility of a hemorrhage should be considered in evaluating the medical condition in any anticoagulated patient. Major or severe bleeding may occur and, regardless of location, may lead to disabling, life-threatening or even fatal outcomes.
Since the adverse event profiles of the patient populations treated with rivaroxaban for different indications are not interchangeable, a summary description of major and total bleeding is provided by indication, in Table 5 for VTE prevention in patients undergoing elective THR or TKR surgery, in Table 6 for Treatment of VTE and prevention of recurrent DVT and PE, in Table 7 for stroke prevention in atrial fibrillation, and in Table 8 for prevention of stroke, myocardial infarction (MI), cardiovascular (CV) death, acute limb ischemia (ALI) and mortality in patients with CAD with or without PAD or prevention of atherothrombotic events in patients with symptomatic PAD at demonstrated high risk of major adverse limb events (MALE) or […]
1 Special Populations ............................................................................................... 1 Pregnant Women ....................................................................................................
2 Breast-feeding ......................................................................................................... 3 Pediatrics.................................................................................................................
4 Geriatrics ................................................................................................................. 21 8 ADVERSE REACTIONS................................................................................................
1 Adverse Reaction Overview .................................................................................. 2 Clinical Trial Adverse Reactions ............................................................................ 1 Clinical Trial Adverse Reactions – Pediatrics...........................................................
3 Less Common Clinical Trial Adverse Reactions ..................................................... 4 Abnormal Laboratory Findings: Hematologic, Clinical Chemistry and Other Quantitative Data Clinical Trial Findings ...........................................................................
5 Post-Market Adverse Reactions............................................................................ 39 9 DRUG INTERACTIONS ............................................................................................... 2 Drug Interactions Overview ..................................................................................
4 Drug-Drug Interactions ......................................................................................... 5 Drug-Food Interactions ......................................................................................... 6 Drug-Herb Interactions .........................................................................................
7 Drug-Laboratory Test Interactions........................................................................ 43 10 CLINICAL PHARMACOLOGY ....................................................................................... 1 Mechanism of Action ............................................................................................
2 Pharmacodynamics ............................................................................................... 3 Pharmacokinetics ..................................................................................................
47 11 STORAGE, STABILITY AND DISPOSAL ......................................................................... 54 12 SPECIAL HANDLING INSTRUCTIONS........................................................................... 54 PART II: SCIENTIFIC INFORMATION ......................................................................................
55 13 PHARMACEUTICAL INFORMATION ........................................................................... 55 14 CLINICAL TRIALS .......................................................................................................
1 Clinical Trials by Indication ................................................................................... 2 Comparative Bioavailability Studies ..................................................................... 94 15 MICROBIOLOGY .......................................................................................................
98 16 NON-CLINICAL TOXICOLOGY ..................................................................................... 98 17 SUPPORTING PRODUCT MONOGRAPHS .................................................................... 99 PATIENT MEDICATION INFORMATION ...............................................................................
100 RIVA RIVAROXABAN […]